Shares of St. Jude Medical fell after the FDA released a plant inspection report that found problems in the company’s testing and oversight of an electrical wire, or lead, that connects an implanted defibrillator to a patient’s heart. The FDA report raises the prospect of potential agency action. St. Jude executives have repeatedly insisted the lead is safe.
St. Jude Medical stock falls after FDA report
| New York Times November 25, 2012
Read it all, now.
Don't miss any of your favorite stories again. Read the stories that matter to you as much as you want, whenever you want when you subscribe to BostonGlobe.com.
Get full access today for just 99¢